Question 1

What is Halozyme Therapeutics's preferred stock par value per share?

Accepted Answer

Halozyme Therapeutics (HALO) reported preferred stock par value per share of $0.00 in Q2 2026.

Question 2

How has Halozyme Therapeutics's preferred stock par value per share changed year-over-year?

Accepted Answer

Halozyme Therapeutics's preferred stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.

Question 3

What is the long-term trend for Halozyme Therapeutics's preferred stock par value per share?

Accepted Answer

Over 5 years (2020 to 2025), Halozyme Therapeutics's preferred stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.

Question 4

What does preferred stock par value per share mean?

Accepted Answer

The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.

Line item	June 30,2026	December 31,2025
Total liabilities	2,433,865	2,476,509
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding	—	—
Common stock - $0.001 par value; 300,000 shares authorized; 114,042 and 117,782 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	114	118
Additional paid-in capital	—	12,002
Accumulated other comprehensive loss	(7,830)	(18,092)
Retained earnings	151,259	54,786

Preferred Stock Par Value Per Share at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about Halozyme Therapeutics's preferred stock par value per share.

Halozyme Therapeutics HALO Preferred Stock Par Value Per Share